Novo Nordisk A/S (NVO) Appoints Anne Phillips, M.D., as Vice President for Clinical, Medical and Regulatory Affairs for North Am

Novo Nordisk A/S (NVO) Appoints Anne Phillips, M.D., as Vice President for Clinical, Medical and Regulatory Affairs for North America


PRINCETON, N.J., Jan. 3, 2011 /PRNewswire/ -- Novo Nordisk, a global healthcare company focusing on diabetes care, today announced the appointment of Anne Phillips, M.D., as vice president, Clinical Development, Medical and Regulatory Affairs for North America. Dr. Phillips reports directly to Jerzy Gruhn, president, Novo Nordisk Inc., the company's U.S. Affiliate, and senior vice president for Novo Nordisk A/S North America. She will serve as a member of the U.S. Executive Team.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO)

Dr. Phillips brings more than 20 years of medical, research, and regulatory experience to her new role. She'll be leading the North American clinical development and medical affairs activities across the diabetes and biopharmaceutical franchises, as well as regulatory affairs and medical operations.

"We're pleased to welcome Dr. Phillips and her significant clinical development and regulatory experience to the leadership team here at Novo Nordisk," said Jerzy Gruhn, president, Novo Nordisk Inc. "Our development activity is moving at an incredible pace, and she brings the right mix of global and regional perspective that will complement our efforts."

Dr. Phillips comes to Novo Nordisk from GlaxoSmithKline, where she worked within the company's Research and Development organization since 1998. She served initially as a medical advisor, and advanced into leadership roles, most recently as Vice President, Medicine Development Leader within GSK's Oncology R&D organization. Between 2005 and 2009, Dr. Phillips headed a global team which supported Phase II-IV activities in the metabolic clinical area and provided leadership into development of all GSK metabolic and cardiovascular molecules and assets.

Dr. Phillips received her medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada.

She replaces Dr. Per Falk, who was promoted to senior vice president for Novo Nordisk's Biopharmaceuticals Research Unit in Denmark.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.

SOURCE Novo Nordisk

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.